Vaccine Info

TNX-801 Monkeypox Vaccine

Authored by
Staff
Last reviewed
July 29, 2022
Fact checked by
Robert Carlson, MD
Share

TNX-801 Monkeypox Vaccine Description

TNX-801 is a vaccine candidate being developed to protect humans against monkeypox and smallpox infection.

TNX-801 was developed as part of a research collaboration between Tonix and Professor David Evans, Ph.D. and Ryan Noyce, Ph.D., the Department of Cell Biology, University of Alberta.

TNX-801 is a live virus vaccine based on synthesized horsepox, the sequence of the 1976 natural isolate Mongolian horsepox clone MNR-763.

Molecular analysis of DNA sequences suggests that TNX-801 is closer than modern smallpox vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner in 1798.

TNX-801 Clinical Trials

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan, seek regulatory approval, and conduct a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.

“KEMRI is excited to plan this clinical trial with Tonix and ultimately to lead the trial,” said Professor Samuel Kariuki, Director General and CEO of KEMRI. “Monkeypox has spread in Central and West Africa, and there’s a concern that we could begin seeing cases in Eastern and Central Africa or from foreign travelers. Recently, monkeypox has been reported in over 30 countries outside of Africa that were not endemic to the monkeypox virus. We are grateful that Tonix is committed to sponsoring clinical studies and making TNX-801 available for this important problem.”

Clinical Trials

No clinical trials found